(44) showed that sorafenib could inhibit and prevent migration of a colony of HCC cells after RFA, that overexpression of IF1 could attenuate the effect of sorafenib in these cells, and that inhibition of IF1 could improve the therapeutic effect of sorafenib. Here, ATP5IF1 is linked to hepatocellular carcinoma.